• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

US - CDC: Labcorp To Begin Monkeypox Testing Today, Doubling Nationwide Testing Capacity - July 6, 2022

sharon sanders

Editor-in-Chief & President
via email


Media Statement

FOR IMMEDIATE RELEASE
Wednesday, July 6, 2022

Contact: CDC Media Relations
(404) 639-3286

Labcorp To Begin Monkeypox Testing Today, Doubling Nationwide Testing Capacity

Starting today, Labcorp will begin testing for monkeypox using CDC’s orthopoxvirus test (which detects all non-smallpox related orthopoxviruses, including monkeypox).

“The ability of commercial labs to test for monkeypox is a key pillar in our comprehensive strategy to combat this disease,” said CDC Director Rochelle Walensky, M.D., M.P.H. “This will not only increase testing capacity but will make it more convenient for providers and patients to access tests by using existing provider-to-lab relationships.”

Labcorp will offer this testing at its largest facility in the United States and will be able to accept specimens from anywhere in the country. Labcorp expects to be able to perform up to 10,000 tests per week, which will double the current capacity provided through CDC’s
Laboratory Response Network (LRN), which itself has rapidly expanded testing capacity over the last seven weeks.

On June 22,
HHS announced that five commercial laboratory companies would soon begin offering monkeypox testing. Since then, CDC shipped the tests to the laboratories and their employees have been trained on their administration, among other steps.

Anyone with a rash that
looks like monkeypox should talk to their healthcare provider about whether or not they need to get tested, even if they don’t think they had contact with someone who has monkeypox. Healthcare providers, nationwide, can order the orthopoxvirus test from Labcorp just as they normally would order other tests. The public will not be able to go to a Labcorp lab and submit a specimen. Labcorp will use electronic laboratory reporting (ELR) to report results to jurisdictions as outlined in the CDC reporting guidance.

CDC anticipates
additional commercial laboratories will come online and monkeypox testing capacity will continue to increase throughout the month of July. Healthcare providers can access information on Labcorp’s test at www.labcorp.com/monkeypox*. The latest CDC information on monkeypox is available at www.cdc.gov/monkeypox.

*Linking to a non-federal site does not constitute an endorsement by HHS or any of its employees of the sponsors or the information and products presented on the site.
 
Back
Top